Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Today's Featured Company
ImmunoCellular Therapeutics Ltd.: (IMUC:NYSE.MKT) ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company has concluded a Phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. More >
Streetwise Expert Interviews
This fall, presidential candidate Hillary Clinton once again proposed price caps on out-of-pocket payments for pharmaceuticals. Liana Moussatos of Wedbush Securities has followed the price-cap discussion since the 1990s, and says the issue is more political than real. Given that, she tells The Life Sciences Report about some up-and-coming companies with products she believes are likely to make big improvements in the health of patients and the wallets of investors.(11/24/15) More >
Oppenheimer & Co.'s Rohit Vanjani sees clear ways to profit from generic drug companies despite recent political blowups, and identifies a handful of select generic drug and specialty pharma stocks that still have pricing power and margin expansion potential. (11/18/15) More >
Learn More About Companies in This Issue
|Alliance for Regenerative Medicine|
BrainStorm Cell Therapeutics Inc.
BriaCell Therapeutics Corp.
|Cynata Therapeutics Ltd.|
RepliCel Life Sciences Inc.
|Nobilis Health Corp.|